Matches in SemOpenAlex for { <https://semopenalex.org/work/W2999423218> ?p ?o ?g. }
Showing items 1 to 71 of
71
with 100 items per page.
- W2999423218 abstract "ABSTRACT Molecular imaging has rapidly acquired importance for the evaluation of cancer patients, being complementary to conventional imaging methods as CT, MR and US. Among molecular imaging procedures, Positron Emission Tomography (PET) is the most diffuse and rapidly growing, and at present it is routinely used in patients affected by a large variety of malignant neoplastic diseases. Many papers in the literature have already demonstrated the utility of this imaging technique whose capabilities have been furthermore developed by the introduction of hybrid scanners, particularly PET-CT. The combination of functional data (given by PET) and anatomic details (provided by CT) allows to significantly increase diagnostic accuracy, essentially due to a better specificity. The usefulness of PET relies on its capability of investigating molecular processes by means of specific radiotracers, with the most employed being 18F-DeoxyGlucose (FDG). FDG PET scans give important information about tissues glucose consumption, usually very increased in the great majority of solid malignancies. A number of indications for PET use in clinical oncology have already been validated. Main indications are: characterization of uncertain lesions; staging; early evaluation of response to therapy; evaluation of residual disease at therapy completion and identification of relapse during follow-up. Despite FDG scans represent more than 90% of all PET scans, other positron emitter tracers are available and each one may be specific for different neoplastic diseases. In fact some malignancies do not show increase in glucose consumption and are almost invisible with FDG: therefore other tracers have been developed to study other metabolic pathways. Tracers already in clinical use include Choline (labeled with 11C or 18F), a marker of cell membrane metabolism particularly useful for prostate cancer detection; 18F-Tyrosine and 11C-Methionine, which enable to study proteic metabolism and are successfully employed for CNS neoplastic diseases; 18F-DOPA and 68Ga-DOTA-NOC, useful in neuroendocrine tumors. Disclosure The author has declared no conflicts of interest." @default.
- W2999423218 created "2020-01-23" @default.
- W2999423218 creator A5060396380 @default.
- W2999423218 date "2012-09-01" @default.
- W2999423218 modified "2023-09-26" @default.
- W2999423218 title "Molecular Imaging with Pet/Ct: Fdg and Beyond" @default.
- W2999423218 doi "https://doi.org/10.1016/s0923-7534(20)34282-4" @default.
- W2999423218 hasPublicationYear "2012" @default.
- W2999423218 type Work @default.
- W2999423218 sameAs 2999423218 @default.
- W2999423218 citedByCount "0" @default.
- W2999423218 crossrefType "journal-article" @default.
- W2999423218 hasAuthorship W2999423218A5060396380 @default.
- W2999423218 hasBestOaLocation W29994232181 @default.
- W2999423218 hasConcept C121608353 @default.
- W2999423218 hasConcept C126322002 @default.
- W2999423218 hasConcept C126838900 @default.
- W2999423218 hasConcept C127077266 @default.
- W2999423218 hasConcept C136339569 @default.
- W2999423218 hasConcept C150903083 @default.
- W2999423218 hasConcept C182752723 @default.
- W2999423218 hasConcept C19527891 @default.
- W2999423218 hasConcept C207001950 @default.
- W2999423218 hasConcept C2775842073 @default.
- W2999423218 hasConcept C2989005 @default.
- W2999423218 hasConcept C2994114330 @default.
- W2999423218 hasConcept C3017724952 @default.
- W2999423218 hasConcept C71924100 @default.
- W2999423218 hasConcept C86803240 @default.
- W2999423218 hasConceptScore W2999423218C121608353 @default.
- W2999423218 hasConceptScore W2999423218C126322002 @default.
- W2999423218 hasConceptScore W2999423218C126838900 @default.
- W2999423218 hasConceptScore W2999423218C127077266 @default.
- W2999423218 hasConceptScore W2999423218C136339569 @default.
- W2999423218 hasConceptScore W2999423218C150903083 @default.
- W2999423218 hasConceptScore W2999423218C182752723 @default.
- W2999423218 hasConceptScore W2999423218C19527891 @default.
- W2999423218 hasConceptScore W2999423218C207001950 @default.
- W2999423218 hasConceptScore W2999423218C2775842073 @default.
- W2999423218 hasConceptScore W2999423218C2989005 @default.
- W2999423218 hasConceptScore W2999423218C2994114330 @default.
- W2999423218 hasConceptScore W2999423218C3017724952 @default.
- W2999423218 hasConceptScore W2999423218C71924100 @default.
- W2999423218 hasConceptScore W2999423218C86803240 @default.
- W2999423218 hasLocation W29994232181 @default.
- W2999423218 hasOpenAccess W2999423218 @default.
- W2999423218 hasPrimaryLocation W29994232181 @default.
- W2999423218 hasRelatedWork W131213858 @default.
- W2999423218 hasRelatedWork W1606296163 @default.
- W2999423218 hasRelatedWork W1973434317 @default.
- W2999423218 hasRelatedWork W2004775497 @default.
- W2999423218 hasRelatedWork W2006875080 @default.
- W2999423218 hasRelatedWork W2018447620 @default.
- W2999423218 hasRelatedWork W2050069758 @default.
- W2999423218 hasRelatedWork W2081099240 @default.
- W2999423218 hasRelatedWork W2098637174 @default.
- W2999423218 hasRelatedWork W2113775666 @default.
- W2999423218 hasRelatedWork W2124973383 @default.
- W2999423218 hasRelatedWork W2149672328 @default.
- W2999423218 hasRelatedWork W2333229623 @default.
- W2999423218 hasRelatedWork W2913088135 @default.
- W2999423218 hasRelatedWork W2939693858 @default.
- W2999423218 hasRelatedWork W2958027432 @default.
- W2999423218 hasRelatedWork W3037129905 @default.
- W2999423218 hasRelatedWork W3162261612 @default.
- W2999423218 hasRelatedWork W61062999 @default.
- W2999423218 hasRelatedWork W2559900858 @default.
- W2999423218 isParatext "false" @default.
- W2999423218 isRetracted "false" @default.
- W2999423218 magId "2999423218" @default.
- W2999423218 workType "article" @default.